Get started
Author

Luis Felipe Casado Montero

Observed names: L F C Montero, L.F. Casado Montero
ORCID: 0000-0002-8171-0674
Observed ORCID: 0000-0002-8171-0674
OpenAlex ID: A5016332912
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
2015 · V Goede, K Fischer, et al. · Leukemia · 241
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
2021 · Valentín Garcia-Gutiérrez, Alejandro Luna, et al. · Blood Cancer Journal · 44
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis
2026 · Efstathios Kastritis, Giovanni Palladini, et al. · Blood · 27
GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years
2023 · Maria-Victoria Mateos, Bruno Paiva, et al. · Blood · 25
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
2014 · Valentin García‐Gutiérrez, Jose Manuel Puerta, et al. · American Journal of Hematology · 8
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
2024 · Lucía Pérez-Lamas, Raquel de Paz Arias, et al. · Annals of Hematology · 5
Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients
2025 · Wojciech Jurczak, Michal Kwiatek, et al. · Blood · 4
PDF
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
2024 · Jeff P. Sharman, Luca Laurenti, et al. · Blood · 4
PDF
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
2020 · Adrián Alegre, Javier de la Rubia, et al. · HemaSphere · 4
PDF
Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
2024 · Noemi Puig, Bruno Paiva, et al. · Blood · 3
PDF
Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure
2020 · Alejandro Luna, Natalia Estrada, et al. · Blood · 3
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
2017 · Steve Schey, Luis Felipe Casado Montero, et al. · Oncology and Therapy · 3
PDF
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial
2026 · Jeff P. Sharman, Luca Laurenti, et al. · Blood · 2
PDF
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
2022 · Sunil Lakhwani, Laura Rosinol Dachs, et al. · Blood · 2
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
2019 · Pau Abrisqueta, Eva González-Barca, et al. · Blood · 2
One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib
2026 · Lucía Pérez-Lamas, Mario Manzanares, et al. · Annals of Hematology · 1
PDF
Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial
2025 · Hyun Yong Jin, Jeff Sharman, et al. · Blood · 1
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
2024 · Sunil Lakhwani, María Victoria Mateos, et al. · Annals of Hematology · 1
Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study
2023 · Lucía Pérez-Lamas, Adrian Segura Diaz, et al. · Blood · 1
PDF
Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial
2023 · Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, et al. · Blood · 1
PDF
Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients
2019 · Ricardo Sanchez, Rosa Ayala, et al. · Blood · 1
Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry
2025 · Jorge Labrador, David Martinez-Cuadron, et al. · Blood
Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial
2025 · Carmen Gonzalez, Marta Lasa, et al. · Blood
Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry
2025 · Jorge Labrador, David Martinez-Cuadron, et al. · Blood
Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy
2025 · Bruno Paiva, Leire Burgos, et al. · Blood
PDF
Works count: 36
Citation count: 383
H-index: 5
I10-index: 4
Year
Topic
Type